Business Description
![Bio-Path Holdings Inc Bio-Path Holdings Inc logo](https://static.gurufocus.com/logos/0C00001898.png?14)
Bio-Path Holdings Inc
NAICS : 325412
SIC : 2834
ISIN : US09057N2018
Description
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.21 | |||||
Equity-to-Asset | -1.49 | |||||
Debt-to-Equity | -0.03 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 16.4 | |||||
3-Year EPS without NRI Growth Rate | 16.4 | |||||
3-Year FCF Growth Rate | 24.9 | |||||
3-Year Book Growth Rate | -77.9 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 25.12 | |||||
9-Day RSI | 31.06 | |||||
14-Day RSI | 34.77 | |||||
6-1 Month Momentum % | -33.87 | |||||
12-1 Month Momentum % | -91.63 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.43 | |||||
Quick Ratio | 0.43 | |||||
Cash Ratio | 0.05 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -39.6 | |||||
Shareholder Yield % | -1.49 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -481.75 | |||||
ROA % | -252.61 | |||||
ROIC % | -1122.79 | |||||
ROC (Joel Greenblatt) % | -1137.5 | |||||
ROCE % | -413.55 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-EBIT | -0.31 | |||||
EV-to-EBITDA | -0.32 | |||||
EV-to-FCF | -0.5 | |||||
Earnings Yield (Greenblatt) % | -322.58 | |||||
FCF Yield % | -195.87 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bio-Path Holdings Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -24.15 | ||
Beta | 0.57 | ||
Volatility % | 83.18 | ||
14-Day RSI | 34.77 | ||
14-Day ATR (€) | 0.001504 | ||
20-Day SMA (€) | 6.56 | ||
12-1 Month Momentum % | -91.63 | ||
52-Week Range (€) | 6.56 - 78.4 | ||
Shares Outstanding (Mil) | 1.84 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Bio-Path Holdings Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Bio-Path Holdings Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Bio-Path Holdings Inc Frequently Asked Questions
What is Bio-Path Holdings Inc(FRA:IBP0)'s stock price today?
The current price of FRA:IBP0 is €6.56. The 52 week high of FRA:IBP0 is €78.40 and 52 week low is €6.56.
When is next earnings date of Bio-Path Holdings Inc(FRA:IBP0)?
The next earnings date of Bio-Path Holdings Inc(FRA:IBP0) is .
Does Bio-Path Holdings Inc(FRA:IBP0) pay dividends? If so, how much?
Bio-Path Holdings Inc(FRA:IBP0) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |